Fibroblast Growth Factor (FGF) signaling pathways have well established roles in skeletal development, with essential functions in both chondrogenesis and osteogenesis. In mice, previous conditional knockout studies suggested distinct roles for FGF receptor 1 (FGFR1) signaling at different stages of osteogenesis and a role for FGFR2 in osteoblast maturation.
Introduction
Osteoprogenitors in the periosteum and bone marrow give rise to matrix producing osteoblasts. As bone grows, osteoblasts can become quiescent bone lining cells, die through apoptosis, or differentiate into osteocytes, long-lived cells that become embedded within the mineralized bone matrix. (1, 2) Although embedded within mineralized bone, osteocytes maintain communication with the periosteum, endosteum, and vasculature through a system of channels that form the osteocyte lacunocanalicular network.
Osteocytes function as sensory cells that respond to mechanical loading and other signals by releasing soluble factors that regulate osteoblast anabolic activity, mineral homeostasis, and osteoclast activity. In response to mechanical loading, osteocytes produce prostaglandin E2 which inhibits expression of Sclerostin, a negative regulator of anabolic Wnt signaling in osteoblasts. (3) (4) (5) (6) (7) Osteocytes also respond to parathyroid hormone (PTH), which likewise functions to suppress Sclerostin, accounting for some of the anabolic effects of PTH. (8) Osteocytes are a major source of the cytokine receptor activator of NFkB ligand (RANKL). Mechanical unloading and PTH signaling stimulate RANKL expression in osteocytes. (8) (9) (10) (11) Osteocytes are also a major source of FGF23, an endocrine member of the Fibroblast Growth Factor (FGF) family that primarily signals to the kidney proximal tubules to suppress phosphate resorption. (12, 13) Fibroblast Growth Factor (FGF) signaling has well established roles in bone development with essential functions in both chondrogenesis and osteogenesis. (14) In humans, mutations in FGF receptors (FGFRs) 1 and 2 that affect osteogenesis are found in Crouzon, Apert, Pfeifer, and Bent bone dysplasia syndromes. These mutations result in ligand dependent activation of the mutant FGFR and, in some cases, change in the ligand binding specificity of the FGFR. The only documented example of a FGFR loss of function mutation occurs in CATSHL syndrome, in which loss of FGFR3 results in skeletal overgrowth due to increased chondrogenesis. (14, 15) FGFRs are expressed in most, if not all, skeletal lineages throughout development, and in mature bone. Fgfr1 is expressed throughout limb bud mesenchyme at similar levels in condensing and surrounding cells. In condensing mesenchyme that will give rise to skeletal tissue, Fgfr2 expression increases relative to the surrounding mesenchyme. (16) (17) (18) (19) (20) (21) Cells in the periphery of the mesenchymal condensation form the perichondrium and periosteum and express both Fgfr1 and
Fgfr2
. (17, 20) In the definitive periosteum of developing bone, Fgfr1 is expressed in mesenchymal progenitors and Fgfr2 is expressed in differentiating osteoblasts. (22) (23) (24) (25) (26) In the periosteum of mature bone, FGFR2 expression is lost, while FGFR1 expression persists in a subpopulation of perivascular cells, some of which express the pericyte marker NG2. (27) During fracture repair, expression of both FGFR1 and FGFR2 are increased, (28) and both FGFR1 and FGFR2 are expressed in periosteal derived mesenchymal stem cells. (27) These expression patterns suggest the potential for both unique and redundant functions of Fgfr1 and Fgfr2 in the osteoblast lineage.
Conditional inactivation of Fgf ligands and receptors in skeletal lineages has been a successful approach to identify function during development and following injury. Conditional inactivation of
Fgfr1 and Fgfr2 in limb bud mesenchyme (using Prx1-Cre), or inactivation of Fgfr1 in all mesenchyme (using T(brachyury)-Cre) causes severe skeletal hypoplasia, (29, 30) whereas inactivation of Fgfr1 or Fgfr2 in distal limb bud mesenchyme (using AP2-Cre) causes only a mild skeletal phenotype, (31, 32) suggesting redundancy between FGFRs 1 and 2 in distal limb mesenchyme. Conditional inactivation of Fgfr1 in osteoprogenitor cells using Col2a1-Cre results in increased proliferation and delayed differentiation and matrix mineralization, and conditional inactivation of Fgfr1 in committed osteoblasts using Col1a1-Cre causes enhanced mineralization and cortical bone thickening in 5-to 8-month-old mice.
(23) However, the mechanisms by which FGFR1 affects bone development and growth are not known. In contrast to Fgfr1, mice conditionally lacking Fgfr2 in all bone lineages or harboring a mutation in the mesenchymal splice variant of Fgfr2 (Fgfr2c), show impaired ossification, and decreased bone mineral density, suggesting that Fgfr2 is a positive regulator of osteoblast maturation. (17, 33) The function of FGFR2
in mature osteoblast lineages is not known.
In this study, we investigated the bone-specific function of Fgfr1 and Fgfr2 in mature osteoblast/osteocyte-specific static and inducible conditional knockout mice. We find that mice 
Materials and Methods

Mice
Mice were housed in a pathogen-free facility and handled in accordance with standard use protocols, animal welfare regulations, and the NIH Guide for the Care and Use of Laboratory Animals. All protocols were approved by the Washington University Animal Studies Committee. (36) ROSA Tomato (Ai9 allele), (37) ROSA mTmG , (38) mice have been previously described. All mice for these studies are maintained on a mixed 
MicroCT and DXA Imaging
In vivo microCT was done on the right tibia and femur to evaluate cortical and cancellous bone measures over time (VivaCT 40, Scanco Medical, Wayne, PA; X-ray tube potential 70 kV, integration time 300 ms, X-ray intensity 114 µA, isotropic voxel size 21 µm, frame averaging 1, projections 1024, medium resolution scan). Measurements were made according to recommended standards, (39) with cortical bone measured for 1 mm (48 slices) at a location 5 mm proximal to the tibia fibula junction: total area (T.Ar), bone area (B.Ar), cortical thickness (Ct.Th), tissue mineral density (TMD), and polar moment of inertia (pMOI). Metaphyseal bone was analyzed from a region 600 µm (28 slices) distal to the proximal growth plate in the tibia and proximal to the distal growth plate in the femur. Because of the blurred distinction between the cortical shell and the adjacent cancellous bone in the DCKO mice at ages > 12 weeks, we analyzed all tissue inside the periosteal margin (cortical shell + cancellous bone). Outcomes were:
total volume (TV), bone volume (BV), bone volume to total volume ratio (BV/TV), and volumetric bone mineral density (vBMD). In vivo dual energy X-ray absorptiometry (UltraFocus100 DXA module, Faxitron, Tuscon, Arizona) was used to measure percent fat, bone mineral content (BMC) and areal bone mineral density (aBMD) for the whole body of the mouse (excluding the head). To evaluate growth, body weight was recorded prior to each scan. Mice were scanned at 6, 12, 18, 24 and 32 weeks of age. For the Dmp1-CreER; Fgfr1 f/f ; Fgfr2 f/f mice the bones were scanned ex vivo (X-ray tube potential 55 kV, integration time 300 ms, X-ray intensity 145 µA, isotropic voxel size 10 µm, frame averaging 1, projections 2048, high resolution scan), embedded in 2% agarose.
Dynamic Histomorphometry
To mark bone formation, 12-week-old mice were injected with calcein green (10 mg/kg, IP, Sigma) and 5 days later with alizarin red (25 mg/kg, IP, Sigma), which was given 2 days prior to euthanasia. Tibia were embedded in poly-methyl methacrylate (plastic) and 100 μm thick crosssections of the diaphysis were cut 5 mm proximal to the tibiofibular junction. Sections were mounted to glass slides and polished to a thickness of approximately 30 μm. To visualize the calcein and alizarin labels fluorescent images were taken (Olympus IX51 with Olympus DP70 camera or Leica TCS SPE Confocal). Following published standards (40) , the bone sections were analyzed for mineral apposition rate (MAR), mineralizing surface per bone surface (MS/BS) and bone formation rate per bone surface (BFR/BS) on the endocortical (Ec) and periosteal (Ps) surfaces (BIOQUANT OSTEO, BIOQUANT Image Analysis Corporation, Nashville, TN).
Biomechanics
At 24 weeks age the mechanical properties of the femurs were evaluated with mechanical testing. Prior to testing, the midshaft of these bones (100 slices, 2.1 mm) were imaged with microCT to determine bone morphology (VivaCT 40, Scanco Medical, same parameters as above). After scanning, the femurs were prepared for three-point bending (span = 7 mm). Bones were preloaded to -0.3 N, then a displacement ramp of 0.1 mm/s was applied until failure (Dynamight 8841, Instron, Norwood, MA). As recommended by Jepsen et al., (41) the structural mechanical properties acquired from bending tests were stiffness, yield load, maximum load, post-yield displacement, and work-to-fracture. In combination with the bone morphology (moment of inertia) and beam theory, the estimated material properties of Young's modulus, yield stress, and maximum stress were calculated. After whole-bone testing was completed, reference point indentation (RPI) testing was done at four locations near the midshaft (two on each side of the break 
Determination of osteocyte density and viability
Osteocytes were histologically categorized as alive, dying, and dead based on their appearance on H&E stained cortical sections (see Figure 5J below). Alive cells were characterized by a whole nucleus with little to no empty space in the lacuna. Dying cells were identified morphologically as having either a fragmented nucleus or a small polarized nucleus within an otherwise empty lacuna. Dead cells were identified as having little or no hematoxylinstained material in an otherwise empty lacuna. A small number of histological features (<10%)
could not be assigned a definitive category and were not counted. These may represent histological sectioning artifacts or ossified lacunae. Osteocytes from all three categories were counted in the anterior tibial cortex in a 3 mm region beginning 1 mm from the growth plate.
Osteocyte density was calculated by dividing the number of counted cells/lacunae by the area of cortical bone. Cortical bone area was quantified by measuring the total bone area in the analysis region and then subtracting the area of any region inside this total bone area that was not cortical bone, e.g. marrow space or other cavities.
Real-time quantitative PCR (RT-qPCR)
We 
Sample size and statistics
Based on the coefficient of variation from previous microCT data and a goal to detect a difference in cortical area of 30% (CV=18%), group sample sizes (n) of n=6 mice were chosen.
For quantitative analysis of cell number, cell death, proliferation, or level of gene expression our goal was to detect a 20% difference between control and experimental samples; a sample size of n=4-6 mice were chosen based on average CV (~20%) from recent data. Two-factor ANOVA for DXA, microCT, and histological (osteocyte) measurements; time and genotype were independent factors. Mechanical testing, dynamic histomorphometry, and gene expression measures were evaluated with unpaired t-tests between genotypes groups. All statistical analyses were performed using commercial software (GraphPad Prism 7, La Jolla, CA). Data are represented as mean ± standard deviation (SD). Statistical significance was considered at p < 0.05. In all cases, sample size (n) represents the number of animals per group, which includes approximately equal numbers of males and females.
Results
Increased bone formation in mice lacking Fgfr1 and Fgfr2 in mature osteoblasts
To investigate the role of FGFR1 and FGFR2 signaling in mature osteoblasts and osteocytes, Fgfr1/2 DFF control mice and OC-Fgfr1/2 DCKO mice are healthy and fertile and appeared phenotypically normal. Body weight of all mice in the study increased over time, with no differences between OC-Fgfr1/2 DCKO and Fgfr1/2 DFF mice at any timepoint ( Figure 1A ). In vivo DXA imaging showed that the percent body fat remained consistent from 6 to 24 weeks and was not affected by genotype ( Figure 1B ). However, DXA imaging revealed that whole body bone mineral content (BMC) and areal bone mineral density (aBMD) were both greater in OC-Fgfr1/2 DCKO mice compared to controls, becoming statistically significant at 18 weeks-of-age ( Figure   1C -D). By 24 weeks of age, BMC was 80% higher and aBMD was 30% higher in OC-Fgfr1/2 DCKO mice, with no apparent difference between male and female mice.
To quantitatively assess changes in bone structure over time, control and OC-Fgfr1/2 DCKO mice were monitored by in vivo microCT between 6 and 32 weeks of age. Compared to controls, OC-Fgfr1/2 DCKO mice revealed a progressive accrual of cortical and cancellous bone occurring after 6 weeks of age in both male and female mice ( Figure 1E-H) . In the diaphysis of the bone there were no significant differences in cortical area at 6 weeks of age, but by 12 weeks DCKO mice had 107% greater cortical area (Fig 1E-F) . Furthermore, total area and pMOI were increased compared to age matched controls in mice 12 weeks and older (Supplemental Table S1 ). From 18-32 weeks of age there were dramatic increases in total area, cortical area, pMOI, and cortical thickness. Lower cortical TMD (~8% reduction) was observed in 12-week-old OC-Fgfr1/2 DCKO mice compared to Fgfr1/2 DFF controls. Similar changes were observed in the femur (not shown).
Overall, the shape of the long bones appeared normal over this time course.
Consistent with changes in diaphyseal cortical bone, the tibia metaphyseal compartment also showed greater TV, BV, BV/TV and vBMD in DCKO mice vs. controls; these differences became significant starting at 18 weeks of age and remained elevated through 32 weeks of age ( Figure   1G -H, Supplemental Table S1 ). By 32 weeks of age, BV was 180% greater in OC-Fgfr1/2 DCKO mice. The results were similar for the metaphyseal region in the distal femur (Supplemental Table   S1 ).
To assess the relative contributions of Fgfr1 and Fgfr2 to the regulation of bone growth, we generated Increased whole-bone strength but reduced material properties in OC-Fgfr1/2
DCKO bone
The increased bone mass in OC-Fgfr1/2 DCKO mice suggested that their bones would have increased strength at the whole bone (structural) level. The whole-bone mechanical properties and material properties of femurs from 24-week-old mice were assessed by three-point bending and reference point indentation (RPI). Three-point bending analysis revealed several significant differences in structural mechanical properties of OC-Fgfr1/2 DCKO mice. Compared to controls, OC-Fgfr1/2 DCKO mice showed an 88% increase in yield load, 82% increase in maximum load, and 46% increase in stiffness, but a 71% decrease in post-yield displacement (Figure 2A -D, Supplemental Table S2 ). Work-to-fracture was unaffected by genotype, due the offsetting effects of increased maximum load and decreased post-yield displacement. MicroCT imaging of the femur midshaft showed increased total area and bone area, and an apparent increased porosity in OC-Fgfr1/2 DCKO mice compared to Fgfr1/2 DFF control mice ( Figure 2E ). These features resulted in a 5-fold increase in polar moment of inertia (pMOI) ( Figure 2H ). Estimated material properties, including Young's modulus, yield stress, and maximum stress, were significantly less by 70%, 44%, and 45%, respectively, in DCKO versus controls ( Figure 2F , G, Supplemental Table S2 ).
Increased mineralized bone and increased osteoblast and osteoclast activity in OC-
FGFR1/2 DCKO mice
Histological analysis of 12-week-old mice is consistent with the microCT data, showing increased cancellous and cortical bone in OC-Fgfr1/2 DCKO mice compared to Fgfr1/2 DFF control mice ( Figure 3A) . In contrast, the growth plate showed histologically normal proliferating and hypertrophic chondrocytes ( Figure 3B ). Cortical bone histology of OC-Fgfr1/2 DCKO mice shows relatively normal appearing lamellar bone on the periosteal side but an increase in woven bone on the endocortical side ( Figure 3A) . Mineralization, assessed by Von Kossa staining,
showed complete mineralization of all cortical and cancellous regions ( Figure 3C ).
Dynamic histomorphometry of 12-week-old mice indicated increased anabolic activity in OC- 
Osteocyte loss precedes increased bone accrual
A striking histological feature of OC-Fgfr1/2 DCKO bone histology is the absence of nuclei within osteocyte lacunae, observed in both cortical ( Figure 5 ) and trabecular regions (not shown).
Osteocyte lacunae were histologically scored as alive, dying, or dead, based on lacunar morphology ( Figure 5J ). At 3 weeks of age, OC-Fgfr1/2 DCKO cortical bone showed normal lamellar histology ( Figure 5A, B) . However, quantitation of nucleated lacunae (classified as alive cells) showed a 36% decrease in OC-Fgfr1/2 DCKO tibia compared to Fgfr1/2 DFF control tibia (p<0.01) and a corresponding increase in dying/dead osteocytes ( Figure 5A -C). At 6 weeks of age cortical histology also showed normal appearing lamellar bone; however, there was a 64% decrease in alive osteocytes (p<0.001) and a corresponding increase in dying/dead osteocytes ( Figure 5D-F) . TRAP staining of 3-week-old OC-Fgfr1/2 DCKO mice did not reveal qualitative differences in the abundance or appearance of osteoclasts (not shown).
Twelve-week-old mice showed a layer of normal-appearing lamellar bone on the periosteal side, and a large increase in endocortical woven bone. In both histological domains there was a dramatic absence of alive osteocytes (94% reduction, p<0.001) in OC-Fgfr1/2 DCKO mice compared to Fgfr1/2 DFF controls and a large (54 fold) increase in the number of dead osteocyte lacunae ( Figure 5G-I) . The fragmented appearing osteocyte nuclei suggested apoptosis, which was confirmed by TUNEL assay, which showed abundant staining in OC-Fgfr1/2 DCKO cortical bone, but not in Fgfr1/2 DFF control bone ( Figure 5M, N) . At all three ages examined, the overall density of osteocyte lacunae remained similar in Fgfr1/2 DFF and OC-Fgfr1/2 DCKO mice ( Figure   5K ). Both genotypes showed a moderate (22-24%, p<0.05) decrease in lacunar density between 3 and 12 weeks-of-age. Interestingly, at 3 weeks of age, the average density of alive osteocytes in OC-Fgfr1/2 DCKO mice was similar to that of controls at all time points ( Figure 5L ). This suggests that the density of living osteocytes may be the limiting factor for normal cortical bone growth. Figure 7A , B and
Increased bone formation correlates with activation of Wnt/βCatenin signaling
FGFR requirements for osteocyte survival in mature mice
Supplemental Figure 1 ).
Dmp1-CreER; Fgfr1
f/f ; Fgfr2 f/f (DMP-Fgfr1/2 DCKO) mice and Fgfr1/2 DFF control mice were given tamoxifen chow beginning at 3 weeks of age for 2 weeks to inactivate Fgfr1 and Fgfr2 in osteoblasts and osteocytes. Mice were then aged to 16 weeks and limbs were examined by microCT followed by histology ( Figure 7C ). MicroCT analysis of 16-week-old DMP-Fgfr1/2 DCKO mice showed increased bone area and total area in the mid tibia ( Figure 7D ) and mid femur (not shown). Histological analysis showed increased cortical bone accompanied by osteocyte lacunae that were empty or contained fragmented nuclei ( Figure 7F-I) . Similar to the OC-Fgfr1/2 DCKO mice, DMP-Fgfr1/2 DCKO mice showed positive TUNEL staining throughout cortical bone ( Figure   7J -K).
Discussion
In this report we identify a novel function of FGFR signaling in mature osteoblasts and osteocytes which is required to maintain osteocyte viability. Osteocytes are a source of Sclerostin, a Wnt inhibitory protein product of the Sost gene.
Reduced expression of Sost would be expected to lead to increased Wnt/βCatenin signaling and stimulation of osteoblast anabolic activity. (42) However, in 3-week-old OC-Fgfr1/2 DCKO mice, Sost expression was reduced while Wnt/βCatenin signaling, as assessed by expression of Wnt reporter genes, showed no evidence of activation and in fact was reduced. In contrast, by 12
weeks of age, when most osteocytes were lost, Sost was also reduced and, as expected, some markers of Wnt/βCatenin signaling (Lrp5, Lef1) were upregulated. We posit that increased Wnt/βCatenin signaling beginning between 6 and 12 weeks of age is one factor that contributes to the observed increase in bone formation observed in 12-week and older mice.
The mechanism(s) by which loss of FGFR signaling results in osteocyte loss is not known and could involve regulation of direct cell survival pathways, regulation of the osteocyte lacunocanalicular network or the surrounding extracellular matrix, or other signaling systems in bone that affect osteocyte survival. Regulation of the lacunocanalicular network is particularly attractive given that through its transduction of mechanical force the lacunocanalicular network is important for osteocyte survival. (11, 43) Additionally, osteocyte apoptosis is stimulated by estrogen withdrawal, glucocorticoids, unloading, and microdamage (11, 44, 45) Although the mechanisms by which these events lead to osteocyte apoptosis are poorly understood, our results raise the possibility that altered FGFR signaling may play a role. Examination of mechanisms by which FGFR signaling promotes osteocyte survival will be the subject of future studies.
The increase in bone mass in OC-Fgfr1/2 DCKO is preceded by the initial loss of osteocytes, suggesting that increased bone accrual is secondary to osteocyte loss. This possibility could be tested by pharmacologically inhibiting osteocyte apoptosis with the pan-caspase inhibitor QVD, which has been shown to block osteocyte apoptosis and prevent pathological bone remodeling. (11, (46) (47) (48) At both 3 and 12 weeks of age, we observed increased Fgf23 mRNA expression in cortical bone. Given that the number of viable osteocytes is in decline, this suggests that the increased Fgf23 expression likely occurs in osteoblasts or pre-osteocytes. (49) Interestingly, it has been shown that viable osteocytes, within 100 to 300 µm from dying osteocytes, have increased expression of VEGF and RANKL. (45, 50) We posit that Fgf23 expression may be similarly increased in nearby viable osteocytes or pre-osteocytes in response to their dying neighbors. The mechanisms leading to increased Fgf23 in OC-Fgfr1/2 DCKO mice are not known and likely to be indirect since available data suggests that FGFR1 signaling functions to directly promote Fgf23 expression in osteocytes and bone marrow stromal cells. (51) (52) (53) Furthermore, genetic inactivation of Fgfr1 in osteocytes of Hyp mice, a mouse model of X-linked hypophosphatemia (XLH), reduced the excessive FGF23 levels in osteocytes and partially rescued the bone phenotype in these mice. (54) In contrast, pharmacological activation of FGFR1 in osteoblasts led to increased FGF23 secretion and hypophosphatemia in adult mice. (55) These data support an important role for FGF23/FGFR1 signaling in the control of bone mass and mineralization in vivo, but through a mechanism that is distinct from that in OC-Fgfr1/2 DCKO mice lacking FGFR1 in mature osteoblasts and osteocytes.
The FGF ligands that function in neonatal and juvenile growing bone are not known. FGF2, FGF9, and FGF18 are good candidates since FGF9 and FGF18 have established roles in bone development, (26, (56) (57) (58) (59) (60) (61) (62) (63) and FGF2 has established roles in growing and mature bone. (64) However, loss of FGF2 leads to osteoporosis, suggesting that it functions at a different stage of the osteoblast lineage, or functions through a different FGFR, such as FGFR3, which is also expressed in mature osteoblasts. (65) Future experiments will be required to determine if there is redundancy between FGF2 and FGF9/18, or unique stage-specific activities of these ligands during osteoblast maturation in growing bone.
In conclusion, these studies establish a role for FGFR signaling in the mature osteoblast lineage in growing bone in neonatal and juvenile mice. Loss of FGFR signaling in mature osteoblasts or osteocytes either directly or indirectly leads to osteocyte death, which in turn leads to increased cortical remodeling and eventual bone mass accrual. Future studies will be required to determine whether FGFR signaling has a homeostatic role in mature bone. showing decreased numbers of "alive" osteocytes and increased numbers of "dead" and "dying"
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